Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary

BackgroundCancer of unknown primary (CUP) is a malignant tumor without a known primary lesion with a frequency of 3−5%. It can be divided into favorable and unfavorable prognosis subsets. While recommended treatments are available for the former group, there is no established treatment for the latte...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Risako Suzuki, Kazuyuki Hamada, Ryotaro Ohkuma, Mayumi Homma, Toshiaki Tsurui, Nana Iriguchi, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Yutaro Kubota, Atsushi Horiike, Kiyoshi Yoshimura, Satoshi Wada, Toshiko Yamochi, Takuya Tsunoda
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Subjects:	cancer of unknown primary p16 5-fluorouracil cisplatin PD-1 antibody pembrolizumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1231986/full